Everest Medicines Ltd.

As of June 30, 2026, Everest Medicines Ltd. carries a market capitalization of 8.67B, placing it among publicly traded companies globally. Its enterprise value stands at 8.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Everest Medicines Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of June 30, 2026, Everest Medicines Ltd. has 353.83M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Everest Medicines Ltd. maintains a current ratio of 3.77, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Everest Medicines Ltd.'s stock has declined approximately 31.93% over the past 52 weeks. The 50-day moving average sits at 30.48, while the 200-day moving average is 32.70.

As of June 30, 2026, Everest Medicines Ltd. holds 2.35B in cash and equivalents against 2.30B in total debt, resulting in a net debt position of 466.16M. Total book value stands at 6.04B, with working capital of 2.56B providing operational flexibility.